Explore MIND Foundation’s research initiatives, including clinical trials, surveys, and partner studies in psychedelic science. The page summarizes ongoing, completed, and featured projects that involve data collection and evidence-based research.
MIND Foundation
English
32 weeks
The Research page presents scientific studies and surveys affiliated with or supported by the MIND Foundation. It includes clinical trials, acceptance research, partner studies, and survey-based projects related to psychedelic-assisted therapies and mental health care. Featured studies on the page include the DiMension phase 3 clinical trial, the completed EPIsoDE phase 2b trial, the Acceptance Study on stakeholder attitudes, and partner studies at OVID Clinic Berlin. The page also highlights ongoing, past, and featured survey studies from MIND and its global partners. This content is intended for readers interested in psychedelic research, study participation, and the clinical and societal implementation of psychedelic therapies. It provides a structured overview of the Foundation’s research activity rather than a formal training course.
People interested in psychedelic research, clinical trials, survey studies, and the implementation of psychedelic therapies in mental health care.
European nonprofit research and implementation organization that organizes the INSIGHT Conference and allied public/professional events.
By Atma Journey
This course is made for mental health professionals (in Canada) who want to learn how to work with psychedelics. The course staff includes Mark Haden Anthony Bossis, and many more.
By Ketamine Academy
Spravato FastTrack is an implementation course for clinics that want to add Spravato (esketamine) services. It covers REMS certification, procurement, prior authorization, billing, documentation, and related operational steps.
By Therapsil
Focused short-form trainings in psychedelic safety, harm reduction, and clinical skill. One listed topic is Psychedelic First Aid, presented in collaboration with Neuma Centre.
Next cohort: May 20, 2026